Ana Baramidze, MD

Ana Baramidze, MD, head of the Department of Clinical Researches at the Todua Clinic in Tbilisi, Georgia, explained how clinicians can decide how to cemiplimab, which has a low discontinuation rate.

Cemiplimab demonstrated a 56% overall survival rate, making it a potential option for physicians to use for treating non–small cell lung cancer (NSCLC).

Cemiplimab plus chemotherapy was found to be consistently effective in treating non-small cell lung cancer (NSCLC) and held up in the EMPOWER-Lung 3 trial.